ClinicalTrials.gg
CompletedNCT06397508Updated May 16, 2024

Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

A Phase 1 interventional study of AGMB-129 in Healthy Volunteers, sponsored by Agomab Spain S.L.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Agomab Spain S.L. (part of Agomab Therapeutics NV) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, open-label, single-dose, randomized, 3-period cross-over, Phase 1 study in healthy adult participants to assess the BA of AGMB-129 tablet formulation relative to that of the reference capsule formulation and to assess the effect of food on the BA of a single oral dose of the AGMB-129 tablet formulation.

A total of 24 participants will be enrolled. Participants will be randomized to 1 of 6 intervention sequences (Williams design) according to a 6-sequence, 3-period design. In 3 sequential intervention periods, each participant will receive 3 study interventions, 1 in each intervention period. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Agomab Spain S.L. is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted after Agomab Spain S.L. became part of Agomab Therapeutics NV.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female, between 18 and 55 years old (extremes included) on the date of signing the ICF.
  2. Body weight of at least 50.0 kg for men and 45.0 kg for women, and a (BMI) between 19.0 and 30.0 kg/m2 (extremes included) at screening.
  3. Must be in good health based on medical history, physical examination, vital signs, and 12-lead in the opinion of the investigator at screening.
  4. Total , (AST), and alanine aminotransferase (ALT) must be ≤1.5x (ULN) at screening. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not in the opinion of the investigator. Note: Participants with diagnosed Gilbert's syndrome with total bilirubin >1.5 ULN are eligible for the study if AST and ALT are ≤1.5x ULN.

Key Exclusion Criteria:

  1. Known to AGMB-129 ingredients or history of a significant allergic reaction to AGMB-129 ingredients as determined by the investigator.
  2. Positive serology for virus surface antigen (HBsAg) or anti- virus [HCV] antibodies at screening, or history of hepatitis from any cause except for hepatitis A that was resolved at least 3 months prior to the first IP administration.
  3. History of or a current condition, including positive types 1 or 2 (HIV-1 [2]) antibodies at screening.
  4. Current or history of vasculitis, valvular heart disease, or large vessel vascular disease (such as aneurism or dissection) at screening.
  5. Any illness, judged by the investigator as clinically significant, in the 3 months prior to the first IP administration.
  6. Presence or sequelae of gastrointestinal, liver, kidney (estimated [eGFR] ≤80 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at screening.
  7. History of within the past 5 years prior to screening, except for excised and curatively treated non- basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of cervix which is considered cured with minimal risk of recurrence.
  8. History or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction, e.g., known long syndrome or a QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 ms detected on the 12-lead ECG at screening or Day 1 predose. A first-degree atrioventricular block will not be considered as a clinically significant abnormality.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    1

    ABC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

  • Experimental
    2

    CAB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

  • Experimental
    3

    BCA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

  • Experimental
    4

    CBA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

  • Experimental
    5

    BAC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

  • Experimental
    6

    ACB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions

    Drug: AGMB-129

Interventions

  • Each participant will receive 3 study interventions, 1 in each intervention period

06

What researchers measure

Primary outcomes

  1. Cmax for AGMB-129

    Time frame: From baseline to Day 3

  2. Cmax for MET-158

    Time frame: From baseline to Day 3

  3. Cmax for MET-154

    Time frame: From baseline to Day 3

  4. AUC0-t for AGMB-129

    Time frame: From baseline to Day 3

  5. AUC0-t for MET-158

    Time frame: From baseline to Day 3

  6. AUC0-t for MET-154

    Time frame: From baseline to Day 3

  7. AUC0-∞ for AGMB-447

    Time frame: From baseline to Day 3

  8. AUC0-∞ for MET-158

    Time frame: From baseline to Day 3

  9. AUC0-∞ for MET-154

    Time frame: From baseline to Day 3

Secondary outcomes

  1. Number of participants with adverse events

    To evaluate the safety and tolerability of AGMB-129 in terms of adverse events at every visit

    Time frame: From Screening to Day 5

  2. Number of participants with abnormal clinical laboratory values

    To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit

    Time frame: From Screening to Day 5

  3. Number of participants with abnormal vital signs

    To evaluate the safety and tolerability of AGMB-129 in terms of vital signs at every visit

    Time frame: From Screening to Day 5

  4. Number of participants with abnormal physical exams

    To evaluate the safety and tolerability of AGMB-129 in terms of physical exams at every visit

    Time frame: From Screening to Day 5

07

Study locations

1 site
  • SGS Belgium
    Edegem, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in May 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 3, 2024
StartActual
Apr 2, 2024
Primary completionActual
May 8, 2024
CompletionActual
May 13, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06397508
Lead sponsor
Agomab Spain S.L.
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Apr 2, 2024
Primary completion
May 8, 2024
Completion
May 13, 2024
Last update
May 16, 2024

Study contacts

Philippe Wiesel, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion